← Back
Data updated: Jun 28, 2026
VANCOCIN ITALIA
Pharma Pharmaceuticals
VANCOCIN ITALIA is a pharmaceutical company with 1 FDA-approved products.
2018
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules
FDA Novel Drug Designations
(2018) 1 Novel 1 Priority Review 1 Fast Track
See 1 novel approval →
VANCOCIN ITALIA's Key Drugs
VANCOCIN ITALIA's core commercial portfolio centers on MULPLETA — its most strategically important drugs approved in the last 15 years.
VANCOCIN ITALIA's Recent FDA Approvals
New NDA/BLA approvals for VANCOCIN ITALIA over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
VANCOCIN ITALIA's Therapeutic Areas
Disease areas where VANCOCIN ITALIA has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
VANCOCIN ITALIA Pipeline Snapshot
Active clinical trials for VANCOCIN ITALIA across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • MULPLETA leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2018-07-31
- Latest
- 2018-07-31
- Applications
- 1